Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 15Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Lymphoma, Non-Hodgkin 6Burkitt Lymphoma 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Astrocytoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Waldenstrom Macroglobulinemia 2Uveal Melanoma 2Smoldering Multiple Myeloma 2Sezary Syndrome 2Optic Nerve Glioma 2Oligodendroglioma 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Promyelocytic, Acute 2

Interventions

gallium Ga 68 dotatate 1cediranib 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid cancer, Hurthle cell × Lenalidomide × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡